Solid Biosciences (SLDB) EBITDA (2017 - 2024)
Historic EBITDA for Solid Biosciences (SLDB) over the last 7 years, with Q4 2024 value amounting to -$39.9 million.
- Solid Biosciences' EBITDA fell 7918.71% to -$39.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$129.7 million, marking a year-over-year decrease of 2443.69%. This contributed to the annual value of -$129.7 million for FY2024, which is 2443.69% down from last year.
- According to the latest figures from Q4 2024, Solid Biosciences' EBITDA is -$39.9 million, which was down 7918.71% from -$35.2 million recorded in Q3 2024.
- Over the past 5 years, Solid Biosciences' EBITDA peaked at -$19.0 million during Q2 2020, and registered a low of -$39.9 million during Q4 2024.
- Its 4-year average for EBITDA is -$26.9 million, with a median of -$26.8 million in 2023.
- Its EBITDA has fluctuated over the past 5 years, first soared by 3558.7% in 2023, then tumbled by 7918.71% in 2024.
- Quarter analysis of 4 years shows Solid Biosciences' EBITDA stood at -$21.3 million in 2020, then tumbled by 61.92% to -$34.6 million in 2022, then skyrocketed by 35.59% to -$22.3 million in 2023, then plummeted by 79.19% to -$39.9 million in 2024.
- Its EBITDA stands at -$39.9 million for Q4 2024, versus -$35.2 million for Q3 2024 and -$27.8 million for Q2 2024.